0001392449 2026-01-01 2026-09-30 0001392449 us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001392449 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001392449 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001392449 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001392449 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001392449 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001392449 2026-06-30 0001392449 us-gaap:RetainedEarningsMember 2026-06-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001392449 us-gaap:CommonStockMember 2026-06-30 0001392449 us-gaap:PreferredStockMember 2026-06-30 0001392449 us-gaap:RetainedEarningsMember 2026-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001392449 us-gaap:CommonStockMember 2026-09-30 0001392449 us-gaap:PreferredStockMember 2026-09-30 0001392449 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001392449 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001392449 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001392449 us-gaap:RetainedEarningsMember 2025-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001392449 us-gaap:CommonStockMember 2025-12-31 0001392449 us-gaap:PreferredStockMember 2025-12-31 0001392449 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001392449 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001392449 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001392449 2025-06-30 0001392449 us-gaap:RetainedEarningsMember 2025-06-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001392449 us-gaap:CommonStockMember 2025-06-30 0001392449 2025-09-30 0001392449 us-gaap:RetainedEarningsMember 2025-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001392449 us-gaap:CommonStockMember 2025-09-30 0001392449 us-gaap:PreferredStockMember 2025-09-30 0001392449 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001392449 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001392449 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001392449 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001392449 2024-12-31 0001392449 us-gaap:RetainedEarningsMember 2024-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001392449 us-gaap:CommonStockMember 2024-12-31 0001392449 us-gaap:PreferredStockMember 2024-12-31 0001392449 2025-01-01 2025-09-30 0001392449 2025-07-01 2025-09-30 0001392449 2026-07-01 2026-09-30 0001392449 2025-12-31 0001392449 2026-09-30 0001392449 2026-11-13 iso4217:USD shares iso4217:USD shares 0001392449 false --12-31 false Q3 2026

0.001

10000000

0.001

250000000

20006402

0.00

false false false false

0.001

10000000

10-Q true 2026-09-30 false 000-52622 GREEN PLANET BIOENGINEERING CO., LTD. DE 37-1532842 20807 Biscayne Blvd. Suite 203 Aventura FL 33180 786 279-2900 Yes Non-accelerated Filer true true 20006402

3850

16298

522415 484678

526265

500976

0.001

10000000

0.001

250000000

20006402

20006

609614

-1155885

-1130596

-526265

-500976

8440

8599

25289

19544

-8440

-8599

-25289

-19544

-8440

-8599

-25289

-19544

20006402

20006

609614

-1094754

-465134

-19544

20006402

20006

609614

-1114298

-484678

20006402

20006

609614

-1105699

-476079

-8599

20006402

20006

609614

-1114298

-484678

20006402

20006

609614

-1130596

-500976

-25289

20006402

20006

609614

-1155885

-526265

20006402

20006

609614

-1147445

-517825

-8440

20006402

20006

609614

-1155885

-526265

-25289

-19544

-12448

-37737

-19514

37737 19514

37737

19514

180

1. General Information Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and changed the name to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries which was subsequently divested to One Bio, Corp (“ONE”) on April 14, 2010. In March 2012, the Company became a subsidiary of Global Fund Holdings Corp. (“Global Funds”) an Ontario, Canada Corporation. The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation. The Company’s activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.

2. Summary of significant accounting policies Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant such rules and regulations. They may not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission. The unaudited condensed financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal and recurring adjustments have been made. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026. Use of EstimatesThe preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported. Actual results could differ from those estimates. Significant items that require estimates were accruals of liabilities. Cash and cash equivalentsCash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Balances of cash and cash equivalents in financial institutions may at times exceed the government-insured limits. Loss per shareEarnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of September 30, 2026 and 2025, the Company does not have any common share equivalents outstanding. Fair Value MeasurementsFASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investment measured and reported at fair value are classified and disclosed in one of the following hierarchy: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top;">Level 1 -</td><td style="vertical-align:top;">Quoted prices are available in active markets for identical investments as of the period reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 2 -</td><td style="vertical-align:top;">Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 3 -</td><td style="vertical-align:top;">Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation.</td></tr></tbody></table> Segment ReportOur President and Chief Executive Officer (“CEO”) is the chief operating decision maker who reviews financial information on a basis for purposes of allocating resources and evaluating financial performance. Accordingly, we determined we operate a single reporting segment. Our CEO assesses performance and decides how to allocate resources primarily based on net income which is reported on our Statement of Operations. Total assets on the Balance Sheets represent our segment assets. Recent Changes in Accounting StandardsManagement does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed financial statements.

The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant such rules and regulations. They may not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission. The unaudited condensed financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal and recurring adjustments have been made. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026.

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported. Actual results could differ from those estimates. Significant items that require estimates were accruals of liabilities.

Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Balances of cash and cash equivalents in financial institutions may at times exceed the government-insured limits.

Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of September 30, 2026 and 2025, the Company does not have any common share equivalents outstanding.

FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investment measured and reported at fair value are classified and disclosed in one of the following hierarchy: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top;">Level 1 -</td><td style="vertical-align:top;">Quoted prices are available in active markets for identical investments as of the period reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 2 -</td><td style="vertical-align:top;">Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 3 -</td><td style="vertical-align:top;">Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation.</td></tr></tbody></table>

Our President and Chief Executive Officer (“CEO”) is the chief operating decision maker who reviews financial information on a basis for purposes of allocating resources and evaluating financial performance. Accordingly, we determined we operate a single reporting segment. Our CEO assesses performance and decides how to allocate resources primarily based on net income which is reported on our Statement of Operations. Total assets on the Balance Sheets represent our segment assets.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed financial statements.

3. Going Concern The unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. As at September 30, 2026, the Company has a working capital deficit of $526,265, and accumulated deficit of $1,155,885 and a net loss of $25,289, for the nine months ended September 30, 2026. The Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from a related party of the majority stockholder. This gives rise to substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this filing. The Company’s financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-526265

-1155885

-25289

4. Amount Due to a Related Company The Company relies on a related party of the majority stockholder to advance funds to finance its operating expenses. The Company’s Chief Executive Officer, Chief Financial Officer and Director of the Company is also a director of the related party. The amounts advanced of $522,415 are interest-free, unsecured and are repayable upon demand.

522415

5. Stockholders’ Deficit Series A Preferred stockThe Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend. The Company does not have any issued shares of the preferred stock as of September 30, 2026 and December 31, 2025. Common stockThe Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share. During the nine months ended September 30, 2026, the Company did not issue any shares of common stock or warrants.

10000000

0.001

1,000

1000

250000000

0.001

6. Commitments and Contingencies The Company does not have any commitments and contingencies during the nine months ended September 30, 2026.

7. Subsequent Events The related party advanced the Company $3,850 from October 1, 2026 through the date of filing.

3850